Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication ofHelicobacter pylori

2012 ◽  
Vol 28 (1) ◽  
pp. 78-83 ◽  
Author(s):  
Masahira Haneda ◽  
Mototsugu Kato ◽  
Saori Ishigaki ◽  
Mio Suzuki ◽  
Masakazu Takahashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Serum Pepsinogen ◽  
Cancer Group ◽  
Gastric Cancer Group

SERUM PEPSINOGEN I LEVELS IN GASTRIC CANCER

2013 ◽  
pp. 43-49
Author(s):  
Thi Minh Tam Phan ◽  
Thi Thu Huong Hoang ◽  
Anh Tuyen Nguyen ◽  
Thi Phuong Anh Le ◽  
Nguyen Tuong Van Ha
Keyword(s):  
Gastric Cancer ◽  
Predictive Value ◽  
Area Under The Curve ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Pepsinogen I ◽  
Cancer Group ◽  
And Control ◽  
Group Serum ◽  
Gastric Cancer Group

Objective: Identification of serum Pepsinogen I levels in gastric cancer. Materials and Methods: Serum pepsinogen I levels was measured by enzym-linked immunosorbent assay (ELISA) on 32 patients in the gastric cancer group diagnosed by endoscopy and histology and control group of 30 patients with functional dyspepsia on endoscopy Using the cut-off value: PGI ≤ 70 ng/ml for gastric cancer. Results: Median Pepsinogen I levels in gastric cancer group was 41.07 ng / ml (25% quartile: 27.83 ng / ml, 75% quartile: 61.57 ng/ml) was significantly lower in control group: 102.03 ng / ml (25% quartile: 57.63 ng / ml, 75% quartile: 129.32 ng/ml) (p<0.001). The rate of Serum Pepsinogen I (≤ 70 ng/ml) was 78.1% in patients with gastric cancer, was 26.7% in the control group. Serum Pepsinogen I test in cut-off value ≤ 70 ng/ml had a sensitivity of 78.1%, specificity 73.3%, positive predictive value of 75.8% and the predictive value negative of 75.9% (p <0.001). The results of the ROC curve: area under the curve = 0.846,p <0.0001 at the cut-of of Pepsinogen I levels in our study ≤ 50.83 ng/ml with the optimal sensitivity and specificity were 65.6% and 86.7%. Key words: serum Pepsinogen I, gastric cancer

scholarly journals Clinical significance of Serum Pepsinogen I/II and gastrin-17 determination in gastric cancer diagnosis and prognosis

2018 ◽  
Vol 16 ◽  
pp. 205873921878129 ◽  
Author(s):  
Huiguang Xue ◽  
Aihua Yang ◽  
Fuguo Liu ◽  
Xueguo Sun ◽  
Xishuang Liu
Keyword(s):  
Gastric Cancer ◽  
Gastric Ulcer ◽  
Control Group ◽  
Serum Pepsinogen ◽  
Gastric Function ◽  
Pepsinogen I ◽  
Diagnosis And Prognosis ◽  
Cancer Group ◽  
Ulcer Group ◽  
Gastric Cancer Group

Currently, the diagnosis of atrophic gastritis and gastric cancer are mainly made by endoscopy and histopathology. Our study aimed to explore the practical value of Serum Pepsinogen I/II and gastrin-17 in gastric cancer diagnosis and prognosis. We collected 60 cases of gastric ulcer from February 2015 to November 2016 as gastric ulcer group, and 40 cases of gastric cancer treated in the same period as gastric cancer group. In 3  years after gastric cancer, 20 patients were served as postoperative gastric cancer group, and 70 healthy subjects as control group. The results showed that serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes were tested by enzyme-linked immunosorbent assay (ELISA). The serum PGI level of gastric ulcer group was higher than control group ( P  <  0.05). The serum G-17 concentrations in gastric ulcer group, gastric cancer group, and postoperative gastric cancer group were all higher than control group ( P  <  0.05). The area under receiver operating characteristic (ROC) curve of PGI screening was 0.905 and the best cutoff point was PGI  <  75  µg/L. Their sensitivity and specificity were 87.2% and 75.1%; the area under ROC curve of PGI/PGII rate screening was 0.761 and the best cutoff point was PGI/PGII  <  4. Their sensitivity and specificity were 88.9% and 62.3%. Multi logistical regression showed that the level of serum PGI, PGI, and G-17 and the odds ratio (OR) level of gastric cancer risk were 2.093, 2.653, and 0.494 ( P  <  0.05). The examination of Serum Pepsinogen I/II, gastrin-17, and other serum gastric function indexes can be used in the diagnosis and prognosis of gastric cancer and has a rather high practical value in monitoring recurrence in postoperative gastric cancer patients.

Expression and Clinical Significance of Serum Exosomal miR-375 in Patients with Gastric Cancer

2021 ◽  
Vol 7 (5) ◽  
pp. 3896-3904
Author(s):  
Daoting Deng ◽  
Hong Zhang ◽  
Junxi Liu ◽  
Lina Ma ◽  
Xinrui Lei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Cox Regression Analysis ◽  
Healthy Group ◽  
Cancer Group ◽  
Kaplan Meier ◽  
Gastric Cancer Patients ◽  
Gastric Cancer Group

To explore exosomal miR-375 expression in gastric cancer patients and its relationship with patient prognosis. A total of 53 patients diagnosed with gastric cancer in our hospital from May 2014 to May 2016 were included as the gastric cancer group, and 46 healthy women who came to our hospital for physical examination during the same period were enrolled as the healthy group. Exosomal miR-375 expression level was detected using qRT-PCR, and the diagnostic performance and prognostic significance of exosomal miR-375 in gastric cancer were explored. The gastric cancer group showed increased exosomal miR-375 expression than the healthy group (P< 0.05); Kaplan-Meier survival analysis exhibited that serum exosomal miR-375 has an AUC of 0.778, sensitivity of 69.57%, and specificity of 75.47%, whereas Cox regression analysis showed that the miR-375 expression in exosomes was an independent risk factor affecting the prognosis of gastric cancer patients (P< 0.05). Patient with gastric cancer showed upregulated miR-375 expression in serum exosomes. Serum exosomal miR-375 was found to has positive sensitivity and specificity in the diagnosis of gastric cancer, which may be associated with poor prognosis of gastric cancer patients.

Antral Nodular Gastritis is Strongly Associated With Diffuse-Type Gastric Cancer and Useful for Identifying High-Risk Groups Not Detected by Serum Pepsinogen Tests

2011 ◽  
Vol 140 (5) ◽  
pp. S-312
Author(s):  
Izumi Nishikawa ◽  
Masashi Oka ◽  
Hiroya Nakata ◽  
Tatsuji Tomeki ◽  
Hideyuki Matsunaka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Risk Groups ◽  
Serum Pepsinogen ◽  
Diffuse Type ◽  
Nodular Gastritis ◽  
Diffuse Type Gastric Cancer

Serum Pepsinogen I and Serum Gastrin in the Screening of Atrophic Pangastritis with High Risk of Gastric Cancer

1991 ◽  
Vol 26 (sup186) ◽  
pp. 117-123 ◽  
Author(s):  
K. Varis ◽  
M. Kekki ◽  
M. Härkönen ◽  
P. Sipponen ◽  
I. M. Samloff
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Serum Gastrin ◽  
Serum Pepsinogen ◽  
Pepsinogen I

scholarly journals Combined Gastric and Colorectal Cancer Screening—A New Strategy

2018 ◽  
Vol 19 (12) ◽  
pp. 3854 ◽  
Author(s):  
Michael Selgrad ◽  
Jan Bornschein ◽  
Arne Kandulski ◽  
Jochen Weigt ◽  
Albert Roessner ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Intestinal Metaplasia ◽  
Incidence Rates ◽  
Screening Colonoscopy ◽  
Serum Pepsinogen ◽  
Serum Samples ◽  
Serological Screening ◽  
Increased Risk ◽  
H Pylori

Background: Our aim was to evaluate the feasibility of a serological assessment of gastric cancer risk in patients undergoing colonoscopy in countries with low-to-moderate incidence rates. Methods: Serum samples were prospectively collected from 453 patients (>50 years old) undergoing colonoscopies. Of these, 279 (61.6%) also underwent gastroscopy to correlate the results for serum pepsinogen I and II (sPG-I and sPG-II), sPG-I/II ratio, and anti-H. pylori antibodies with gastric histopathology findings (graded according to the updated Sydney classification and the Operative Link of Gastritis Assessment (OLGA) and the Operative Link for Gastric Intestinal Metaplasia assessment (OLGIM) systems). Results: H. pylori was found in 85 patients (30.5%). Chronic atrophic gastritis was diagnosed in 89 (31.9%) patients. High-risk OLGA (III–IV) stages were present in 24 patients, and high-risk OLGIM stages were present in 14 patients. There was an inverse correlation of sPG-I with the degree of atrophy and intestinal metaplasia (IM), as well as with the respective OLGA (r = −0.425; p < 0.001) and OLGIM (r = −0.303; p < 0.001) stages. A pathological sPG-I result was associated with a relative risk (RR) of 12.2 (95% confidence interval: 6.29–23.54; p < 0.001) for gastric preneoplastic changes. Conclusions: The assessment of serum pepsinogen allows the identification of patients at increased risk of gastric cancer. A prevention strategy of combining a screening colonoscopy with a serological screening for preneoplastic gastric changes should be considered in the general population.

High-risk Population for Gastric Cancer Development Based on Serum Pepsinogen Status and Lifestyle Factors

Helicobacter ◽  
2009 ◽  
Vol 14 (2) ◽  
pp. 81-86 ◽  
Author(s):  
Yutaka Yamaji ◽  
Hirotsugu Watabe ◽  
Haruhiko Yoshida ◽  
Takao Kawabe ◽  
Ryoichi Wada ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Lifestyle Factors ◽  
Cancer Development ◽  
High Risk Population ◽  
Serum Pepsinogen ◽  
Risk Population

Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography

2005 ◽  
Vol 96 (10) ◽  
pp. 713-720 ◽  
Author(s):  
Hiroshi Ohata ◽  
Masashi Oka ◽  
Kimihiko Yanaoka ◽  
Yasuhito Shimizu ◽  
Chizu Mukoubayashi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Digital Radiography ◽  
High Risk Population ◽  
Serum Pepsinogen ◽  
Risk Population ◽  
Gastric Cancer Screening

The effect of CTLA-4 and CD28 gene variants and circulating protein levels in patients with gastric cancer

2017 ◽  
Vol 42 (5) ◽  
Author(s):  
Soykan Arikan ◽  
Alper Gümüş ◽  
Özlem Küçükhüseyin ◽  
Cihan Coşkun ◽  
Saime Turan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Control Group ◽  
Protein Levels ◽  
Cancer Group ◽  
Pcr Rflp ◽  
Gastric Cancer Patients ◽  
Turkish Patients ◽  
Circulating Levels ◽  
Gastric Cancer Group

AbstractObjective:Gastric cancer is one of the most common malignancies worldwide. The risk factors for gastric cancer include environmental and genetic factors. Inflammation and the immune system are known to contribute to the development of the gastric cancer. We examined the influence of critical polymorphisms of CTLA-4 and CD28 genes and circulating protein levels on the etiology of gastric cancer.Methods:Genotyping of SNPs was performed in 55 gastric cancer patients and 105 healthy individuals using the PCR-RFLP method, and circulating levels of sCTLA-4 and sCD28 were measured.Results:There were no significant differences in the genotype and allele distributions of the evaluated SNPs [CTLA-4-318 C>T (rs5742909), CTLA-4+49 A>G (rs231775), CD28 C>T (rs3116496)] between gastric cancer patients and controls (p=0.36, p=0.78, and p=0.80, respectively). The circulating levels of sCTLA-4 and sCD28 were significantly different between the gastric cancer group and the control group (p<0.001 and p<0.001, respectively).Conclusion:The present results suggest that the CTLA-4 and CD28 gene polymorphisms that were evaluated do not play an important role in Turkish patients with gastric cancer. However, sCTLA4 and sCD28 levels were higher in cancer patients and may be useful as an auxiliary parameter in the diagnosis and monitoring of gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document